Waterloo Startup Builds First Quantum Drug Discovery Tool

Scientists in Waterloo, Ontario just built the world's first quantum-enabled tool that could transform how we develop life-saving medications.

High Q Technologies, a startup born from the University of Waterloo, created a revolutionary device called an electron paramagnetic resonance (EPR) spectrometer. This tool helps researchers test new drugs and study diseases like Alzheimer's, but traditional versions have been slow and difficult to use.

The game changer? High Q's version uses superconducting quantum sensors, the same cutting-edge technology that powers quantum computers. The result is a device that's faster, more stable, and far easier to operate than anything available today.

Troy Borneman, the company's principal scientist, led the team that developed the quantum sensor. He credits two University of Waterloo facilities, Transformative Quantum Technologies and the Quantum-Nano Fabrication and Characterization Facility, for giving High Q the ability to build quantum devices right in their own lab.

That in-house capability slashed years off the typical timeline for bringing new technology to market. Instead of waiting for outside manufacturers, the team could test ideas and refine designs on the spot.

The Canada Foundation for Innovation recently spotlighted High Q's achievement, recognizing how the breakthrough could accelerate medical research. EPR spectroscopy has long been essential for understanding how potential drugs interact with the body at a molecular level, making improvements to the technology valuable across the entire pharmaceutical industry.

The Ripple Effect

This isn't just about one faster machine. By making quantum sensors more accessible, High Q is opening doors for researchers who previously couldn't afford or access this level of precision. Drug development typically takes over a decade and costs billions of dollars, with much of that time spent on early-stage testing.

Tools like High Q's quantum spectrometer could compress those timelines, getting promising treatments to clinical trials sooner. For patients waiting for breakthroughs in Alzheimer's research, Parkinson's disease, or other conditions studied using EPR spectroscopy, that acceleration could be life-changing.

Borneman puts it simply: "To me, that's the most exciting thing. Getting this technology accessible and in the hands of people who can make a difference with it."

Canada's quantum technology sector has been growing rapidly, with Waterloo emerging as a global hub thanks to decades of university research and supportive infrastructure. High Q's success shows how academic breakthroughs can translate into real-world tools when researchers have the resources they need.

The quantum spectrometer is already attracting interest from pharmaceutical companies and research institutions eager to test its capabilities in their own labs.